Related Experiment Video
Updated: Aug 17, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Cervimycin A-D: a polyketide glycoside complex from a cave bacterium can defeat vancomycin resistance
Kerstin Herold1, Friedrich A Gollmick, Ingrid Groth
1Leibniz Institute for Natural Products Research and Infection Biology, HKI, Beutenbergstrasse 11a, 07745 Jena, Germany.
Abstract:
Cervimycins A-D are novel polyketide glycosides with significant activity against multi-drug-resistant staphylococci and vancomycin-resistant enterococci. They are produced by a strain of Streptomyces tendae, isolated from an ancient cave. The structures of the cervimycins were determined by performing extensive NMR and chemical degradation studies. All cervimycins have a common tetracyclic polyketide core that is substituted with unusual di- and tetrasaccharide chains, composed exclusively of trideoxysugars; however, they differ in the acetyl and carbamoyl ring substituent and in the highly unusual terminal methylmalonyl and dimethylmalonyl residues.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial Protein Synthesis
Development of Antibiotic Resistance
Antibiotic Selection
